dragon

Azerbaijan Medical Journal

Aim and Scope

Azerbaijan Medical Journal

The Azerbaijan Medical Journal (AMJ) is a peer-reviewed, open-access monthly publication dedicated to advancing medical science and clinical practice through the dissemination of high-quality, original research. The Journal aims to serve as a global platform for researchers, clinicians, and healthcare professionals to share innovative findings, critical reviews, and evidence-based insights that contribute to the understanding, prevention, diagnosis, and treatment of diseases.

AMJ welcomes submissions across a broad spectrum of medical disciplines, including but not limited to:

The Journal particularly encourages contributions from early-career researchers, multidisciplinary teams, and authors from underrepresented regions. All manuscripts undergo rigorous double-blind peer review to ensure scientific integrity, methodological soundness, and relevance to contemporary medical challenges.We invite authors worldwide to submit original articles, review papers, case reports, brief communications, and study protocols that align with the Journal’s mission of promoting excellence, equity, and accessibility in medical scholarship.

📝 Official Submission Process

Manuscripts must be submitted officially through our online system. Please complete the REGISTRATION FORM on our website first to access your Author Dashboard. You may then submit your manuscript for an initial review by our dedicated editorial team to assess its compliance with our journal's policies and scope.

Step-by-Step Submission Process:
  1. 1. Complete registration Form
  2. 2. Access Your Applicant Dashboard
  3. 3. Submit a new article
  4. 4. Fill Out the Submission Form.
    Please ensure you provide a title and abstract for your article, and upload the required document files.
    Accepted formats are PDF, TXT, and DOCX (up to 10MB per file). You may upload up to 5 files.
    The first document file is mandatory.
💡 Need Help?

For technical assistance with submission or registration, please contact:

For general editorial questions or policy inquiries:

Latest Articles

Azerbaijan Medical Journal

AMJ-20-01-2026-12366
The Mental Health Revolution: AI Therapy Apps and VR Treatments Go Mainstream

Author(s): Dr. Lala Aliyeva

Abstract: Background: The global mental health crisis has precipitated an unprecedented shift toward digital therapeutics, with artificial intelligence (AI)-powered therapy applications and virtual reality (VR) exposure treatments transitioning from experimental tools to mainstream clinical interventions. This systematic review examines the efficacy, safety, and accessibility of these emerging modalities compared to traditional cognitive behavioral therapy (CBT). Methods: We conducted a comprehe...
Read More Azerbaijan Medical Journal • 20-01-2026
AMJ-20-01-2026-12365
Tumor-Antigen-Independent Targeting of Solid Tumors by Armored Macrophage-Directed Anti-TREM2 CAR T Cells: Mechanistic Insights and Clinical Applications

Author(s): Dr. Kamal Huseynov

Abstract: Background: Solid tumors present unique challenges for chimeric antigen receptor (CAR) T-cell therapy due to antigen heterogeneity and the immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages (TAMs) expressing triggering receptor expressed on myeloid cells 2 (TREM2) are critical orchestrators of immunosuppression across diverse tumor types. We hypothesized that targeting TREM2+ macrophages rather than tumor cells directly could overcome barriers to CAR-T efficacy ...
Read More Azerbaijan Medical Journal • 20-01-2026
AMJ-20-01-2026-12364
Five-Year Outcomes of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial

Author(s): Dr. Farid Guliyev, Dr. Aysel Mammadova, Dr. Elshan Abbasov, Dr. Nigar Alieva

Abstract: Background: Nasopharyngeal carcinoma (NPC) is a distinct head and neck malignancy endemic to Southeast Asia and North Africa with high rates of recurrence and metastasis. Camrelizumab, a humanized anti-PD-1 monoclonal antibody, demonstrated promising efficacy in combination with chemotherapy in the first-line treatment of recurrent or metastatic (R/M) NPC. However, long-term survival data beyond three years remain limited. Methods: We conducted a secondary analysis of the CAPTAIN-1st Pha...
Read More Azerbaijan Medical Journal • 20-01-2026
AMJ-20-01-2026-12363
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple Negative Breast Cancer: Efficacy and Safety Results from the ASCENT 04/KEYNOTE-D19 Randomized Clinical Trial

Author(s): Dr. Ramil Ibrahimov, Dr. Lala Aliyeva, Dr. Nigar Humbatova, Dr. Orkhan Mammadov, Dr. Sevda Aliyeva, Mammadova

Abstract: Background: Triple-negative breast cancer (TNBC) remains an aggressive subtype with limited therapeutic options in the metastatic setting. Sacituzumab govitecan (SG), an antibody-drug conjugate targeting TROP-2, and pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, have demonstrated independent activity in metastatic TNBC (mTNBC). We hypothesized that combining these agents would enhance anti-tumor immunity and improve clinical outcomes. Methods: ASCENT-04/KEYNOTE-D19 was an int...
Read More Azerbaijan Medical Journal • 20-01-2026
AMJ-20-01-2026-12362
Armored Macrophage-Targeted CAR-T Cells Reset and Reprogram the Tumor Microenvironment and Control Metastatic Cancer Growth: A Phase I/II Clinical Trial

Author(s): Elchin Mammadov

Abstract: Background: Tumor-associated macrophages (TAMs), which commonly express triggering receptor expressed on myeloid cells 2 (TREM2) or folate receptor beta (FOLR2), are enriched in solid tumors and maintain the tumor microenvironment (TME) in an immunosuppressive state. Chimeric antigen receptor T-cell (CAR-T) therapies targeting tumor cells directly have shown limited efficacy in solid malignancies due to antigen heterogeneity and the immunosuppressive TME. Methods: We engineered IL-12-e...
Read More Azerbaijan Medical Journal • 20-01-2026
dragon